Show simple item record

dc.contributor.authorZhao, Y.
dc.contributor.authorBrown, Marc
dc.contributor.authorJones, S. A.
dc.date.accessioned2010-03-25T11:48:34Z
dc.date.available2010-03-25T11:48:34Z
dc.date.issued2010
dc.identifier.citationZhao , Y , Brown , M & Jones , S A 2010 , ' The topical delivery of benzoyl peroxide using elegant dynamic hydrofluoroalkane foams ' , Journal of Pharmaceutical Sciences , vol. 99 , no. 3 , pp. 1384-1398 . https://doi.org/10.1002/jps.21933
dc.identifier.issn0022-3549
dc.identifier.otherPURE: 185238
dc.identifier.otherPURE UUID: 558674d8-7ff7-4b86-b1b0-5d23d400226c
dc.identifier.otherdspace: 2299/4361
dc.identifier.otherScopus: 76649114318
dc.identifier.urihttp://hdl.handle.net/2299/4361
dc.description‘The definitive version is available at www3.interscience.wiley.com '. Copyright Wiley-Liss, Inc. [Full text of this article is not available in the UHRA]
dc.description.abstractFormulating benzoyl peroxide (BPO) in an effective topical product is challenging due to its poor water solubility and chemical instability, but delivering BPO using elegant foams is an attractive solution to this problem. The aim of this work was to investigate how nanoparticle properties influence BPO release and permeation when administrated using dynamic hydrofluoroalkane foams. Lipid (LN, 50 nm) and polymeric (PN, 350 nm) nanoparticles were produced and loaded into topical foams. Drug release and permeation was measured using ultrafiltration and Franz cells studies, respectively. No BPO release was detected when the nanoparticles were stored in the aqueous solvent, but upon administration to silicone membrane the pluronic surfactant-induced LN swelling and BPO delivery (35.7 ± 3.8 µg cm-2 h-1). In the same situation the PN aggregated with a delivery rate of 2.5 ± 0.2 µg cm-2 h-1. Surprisingly the aqueous nanosuspensions delivered BPO at an equivalent rate to the foams despite the poor drug solubility in the dispersing medium presumably due to ultra-rapid BPO solubilization kinetics of the drug in water. The delivery of BPO from the foams (0.1% BPO) was superior compared to the commercial products (5% BPO), but further testing in human skin is required prior to clinical use.en
dc.language.isoeng
dc.relation.ispartofJournal of Pharmaceutical Sciences
dc.titleThe topical delivery of benzoyl peroxide using elegant dynamic hydrofluoroalkane foamsen
dc.contributor.institutionDepartment of Pharmacy
dc.contributor.institutionHealth & Human Sciences Research Institute
dc.contributor.institutionSchool of Life and Medical Sciences
dc.description.statusPeer reviewed
dc.relation.schoolSchool of Life and Medical Sciences
dcterms.dateAccepted2010
rioxxterms.versionofrecordhttps://doi.org/10.1002/jps.21933
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record